In a dramatic turn of events, UroGen Pharma Ltd. finds itself at the center of a class action lawsuit, accused of misleading its investors about the readiness of its lead product for FDA approval. The lawsuit, filed against UroGen Pharma Ltd. (URGN), aims to recover losses for shareholders who were allegedly misled between July 27, 2023, and May 15, 2025.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The core of the complaint revolves around the ENVISION clinical study, which was supposed to demonstrate the effectiveness of UroGen’s flagship product, UGN-102. However, the lawsuit claims that the study was flawed from the start, lacking a concurrent control arm, which is essential for proving the drug’s effectiveness. This oversight, coupled with the company’s failure to address FDA warnings about the study’s design, has cast a shadow over the potential approval of UGN-102. Consequently, the lawsuit argues that the company’s optimistic statements about its business prospects were misleading and lacked a solid foundation.
For those who have suffered financial losses due to these alleged misrepresentations, there is an opportunity to seek recovery. Shareholders who purchased UroGen stock during the specified period are encouraged to visit [this link](https://zlk.com/pslra-1/urogen-pharma-ltd-lawsuit-submission-form?wire=18) to learn more about their rights and the possibility of joining the class action. Importantly, participating in this legal action comes with no cost or obligation.
The lawsuit is spearheaded by Levi & Korsinsky LLP, a firm renowned for its prowess in securities litigation. With over 20 years of experience and a track record of securing substantial settlements for shareholders, Levi & Korsinsky stands as a formidable advocate for investors. Their expertise in handling complex securities cases has earned them a spot among the top securities litigation firms in the United States for seven consecutive years.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue